WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
+2.84%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$14.8B
AUM Growth
+$2.94B
(+25%)
Cap. Flow
+$3.19B
Cap. Flow
% of AUM
21.59%
Top 10 Holdings %
Top 10 Hldgs %
12.57%
Holding
1,027
New
443
Increased
268
Reduced
185
Closed
111
Top Buys
| 1 |
Apple
AAPL
|
$221M |
| 2 |
NVIDIA
NVDA
|
$212M |
| 3 |
Microsoft
MSFT
|
$197M |
| 4 |
Amazon
AMZN
|
$146M |
| 5 |
Arthur J. Gallagher & Co
AJG
|
$130M |
Top Sells
| 1 |
ASML
ASML
|
$125M |
| 2 |
Reddit
RDDT
|
$111M |
| 3 |
Gilead Sciences
GILD
|
$110M |
| 4 |
Permian Resources
PR
|
$84.7M |
| 5 |
Keysight
KEYS
|
$78.7M |
Sector Composition
| 1 | Healthcare | 32% |
| 2 | Technology | 25.72% |
| 3 | Financials | 7.59% |
| 4 | Industrials | 6.89% |
| 5 | Communication Services | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PYCR
376
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $8.8M | 0.06% |
473,690
+24,397
| +5% | +$453K |
|
377
Capricor Therapeutics
CAPR
$308M
| $8.69M | 0.06% |
+629,934
| New | +$8.69M |
|
|
UPB
378
Upstream Bio, Inc. Common Stock
UPB
$1.08B
| $8.66M | 0.06% |
+526,511
| New | +$8.66M |
|
379
Enovis
ENOV
$1.84B
| $8.57M | 0.06% |
195,408
+76,408
| +64% | +$3.35M |
|
380
Ocular Therapeutix
OCUL
$2.37B
| $8.56M | 0.06% |
1,002,435
+2,435
| +0.2% | +$20.8K |
|
381
Masimo
MASI
$8B
| $8.46M | 0.06% |
51,185
+41,885
| +450% | +$6.92M |
|
382
Schneider National
SNDR
$4.3B
| $8.45M | 0.06% |
+288,681
| New | +$8.45M |
|
383
Synopsys
SNPS
$111B
| $8.45M | 0.06% |
+17,415
| New | +$8.45M |
|
|
GRDN
384
Guardian Pharmacy Services, Inc.
GRDN
$1.79B
| $8.41M | 0.06% |
415,120
-153,011
| -27% | -$3.1M |
|
385
Lowe's Companies
LOW
$151B
| $8.41M | 0.06% |
+34,068
| New | +$8.41M |
|
|
FVR
386
FrontView REIT, Inc.
FVR
$274M
| $8.28M | 0.06% |
+456,974
| New | +$8.28M |
|
387
Savara
SVRA
$643M
| $8.25M | 0.06% |
2,686,938
+381,743
| +17% | +$1.17M |
|
388
Spyre Therapeutics
SYRE
$1.03B
| $8.21M | 0.06% |
352,680
+88,424
| +33% | +$2.06M |
|
389
Rocket Pharmaceuticals
RCKT
$354M
| $8.2M | 0.06% |
652,421
+51,358
| +9% | +$646K |
|
390
TJX Companies
TJX
$155B
| $8.18M | 0.06% |
+67,734
| New | +$8.18M |
|
391
International Flavors & Fragrances
IFF
$16.9B
| $8.16M | 0.06% |
96,484
-37,960
| -28% | -$3.21M |
|
392
Phathom Pharmaceuticals
PHAT
$875M
| $8.13M | 0.06% |
1,001,692
-1,571,720
| -61% | -$12.8M |
|
393
Addus HomeCare
ADUS
$2.08B
| $8.04M | 0.05% |
64,176
-16,460
| -20% | -$2.06M |
|
394
Vornado Realty Trust
VNO
$7.93B
| $8.01M | 0.05% |
+190,512
| New | +$8.01M |
|
395
Citigroup
C
$176B
| $7.99M | 0.05% |
+113,578
| New | +$7.99M |
|
396
Olema Pharmaceuticals
OLMA
$570M
| $7.91M | 0.05% |
1,357,479
+3,293
| +0.2% | +$19.2K |
|
397
Allegion
ALLE
$14.7B
| $7.9M | 0.05% |
+60,423
| New | +$7.9M |
|
398
Lantheus
LNTH
$3.72B
| $7.87M | 0.05% |
88,018
+2,340
| +3% | +$209K |
|
399
Shake Shack
SHAK
$4.03B
| $7.84M | 0.05% |
60,378
+3,809
| +7% | +$494K |
|
400
Avery Dennison
AVY
$13.1B
| $7.82M | 0.05% |
+41,803
| New | +$7.82M |
|